Skip to main content
Evidence Snapshot

Tumor necrosis factor

CHEMBL1825 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1825
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tumor necrosis factor as ChEMBL target CHEMBL1825, mapped to UniProt P01375. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tumor necrosis factor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1825
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P01375
Tumor necrosis factor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tumor necrosis factor matters

As of 2026-09-13

Tumor necrosis factor is reviewed as Tumor necrosis factor (UniProt P01375); Tumor necrosis factor shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block.; 10 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 2579 compounds, and 192 assays, with lead potency reaching pChEMBL 10.5.

Disease context
rheumatoid arthritis

Tumor necrosis factor shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABBV-3373, ADALIMUMAB, CERTOLIZUMAB PEGOL.

Start review with rheumatoid arthritis because it currently carries approved-linked support. Linked drugs include ABBV-3373, ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 10 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 2579 compounds, and 192 assays for this target. The dominant activity type is IC50. CHEMBL3640299 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL3640299 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tumor necrosis factor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P01375, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why rheumatoid arthritis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2579
Total Compounds
192
Total Assays
5
Approved Drugs
IC50: 1615.0, KI: 288.0, EC50: 1065.0, KD: 105.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3640299
 10.5 Ki —
No preferred name
CHEMBL3642435
 10.5 Ki —
No preferred name
CHEMBL3640298
 10.3 Ki —
No preferred name
CHEMBL3640339
 10.3 Ki —
No preferred name
CHEMBL3640336
 10.2 Ki —

Approved Drugs

Structure Compound First Approval
POMALIDOMIDE
CHEMBL43452
 2013
LENALIDOMIDE
CHEMBL848
 2005
PREDNISOLONE
CHEMBL131
 1955
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1825